Companies Dominating the Adrenergic Drug Market
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- GSK plc.
- AstraZeneca
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Viatris Inc.
Browse Key Market Insights with Data Illustration:
In the News
- January 11, 2023: The FDA has authorized Airsupra, an inhalation aerosol containing albuterol and budesonide, for the treatment or prevention of bronchoconstriction as needed, as well as to lower the risk of asthma attacks in individuals with asthma who are 18 years of age or older. The medication known as Airsupra is a combination of the beta-2 adrenergic agonist albuterol and the corticosteroid budesonide. It is the first short-acting beta-agonist and inhaled corticosteroid (ICS) combo to be approved in the United States. Furthermore, Airsupra is the first ICS-containing medicine approved in the United States for use as an asthma relief (as opposed to a controller).
- September 27, 2023: Global healthcare leader Viatris Inc. and clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc., which develops and markets small-molecule therapies for the treatment of retinal and refractive eye disorders, announced that the FDA in the United States has approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis caused by parasympatholytic (like tropicamide) or adrenergic agonists (like phenylephrine).
